---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-179404"
form_type: "8-K"
ticker: "RLAY"
cik: "0001812364"
company_name: "Relay Therapeutics, Inc."
filed_at: "2026-04-27T23:59:59+00:00"
generated_at: "2026-05-15T03:54:20.167133+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Relay Therapeutics reports 44% ORR for zovegalisib triplet; plans Phase 3 in frontline breast cancer

## Summary
- ORR of 44% (15/34) in heavily pre-treated, CDK4/6-experienced patients; 85% tumor reduction.
- Grade 3 hyperglycemia 0% despite 47% pre-diabetic; only 3% discontinued zovegalisib due to TRAEs.
- Phase 3 trial of zovegalisib + atirmociclib + AI in 1L PIK3CA-mutated HR+/HER2- breast cancer expected to start early 2027.
- Pfizer to supply atirmociclib and palbociclib for the trial; Relay retains full rights to zovegalisib.
- Median follow-up 7.4 months; 77% of patients remain on study; median PFS not yet mature.

## SEC filing metadata
- accession: 0001193125-26-179404
- form_type: 8-K
- ticker: RLAY
- cik: 0001812364
- company_name: Relay Therapeutics, Inc.
- filed_at: 2026-04-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1812364/000119312526179404/0001193125-26-179404-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1812364/000119312526179404/rlay-20260427.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-179404
- JSON: https://secwatch.observer/filing/0001193125-26-179404.json
- Plain text: https://secwatch.observer/filing/0001193125-26-179404.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.